lisocabtagene maraleucel
bms
['transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'liso-cel']
transform study confirms benefit to liso-cel vs. soc in 2l. impressive crossover data - 61/92 soc pts approved for crossover; 57 rec'd liso-cel; cr 53%, median pfs, efs 6 months; rates of cr, efs, pfs lower in crossover pts - benefit to early 2l liso-cel! #ash22 
Asst. Professor of Medicine, Hematology/Oncology at @PennStHershey, clinical: myeloma #MMSM, lymphoma #lymsm, @Penn alum, @PennStHershey alum. Tweets my own.